AKT kinases as therapeutic targets
Dalal Hassan, Craig W Menges, Joseph R Testa, Alfonso Bellacosa · 2024
Read AKT kinases as therapeutic targets by Dalal Hassan, Craig W Menges, Joseph R Testa, Alfonso Bellacosa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11606119.txt.
Description
Dalal Hassan and co-authors review AKT kinases as drug targets in cancer and other diseases, in work published in 2024. AKT sits at the center of a growth signaling path that also touches inflammation and overgrowth syndromes. When its control slips, tumors can form.
Drugs that block all AKT forms have been tested widely, often in drug combinations. Some show promise, yet resistance and side effects limit their use. The authors discuss aiming at single AKT forms instead, which may work better with less harm. They also cover newer selective blockers, indirect attacks, and the search for markers that predict which patients will respond.
Catalog record
| CREATOR | Dalal Hassan, Craig W Menges, Joseph R Testa, Alfonso Bellacosa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 106 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |